Regulatory and Compliance Updates news (page 2)

27 October 2025
Johnson & Johnson's TREMFYA® Shows Two-Year Remission in Crohn's Disease
TREMFYA® maintains remission in Crohn's disease over 96 weeks, with consistent safety and efficacy in both subcutaneous and intravenous regimens.
24 October 2025
Johnson & Johnson: Nipocalimab Reduces Sjögren’s Disease Activity and Severity
Nipocalimab shows promise in reducing Sjögren’s disease symptoms and autoantibodies, with a favorable safety profile and ongoing Phase 3 trials.
23 October 2025
Merck's KEYTRUDA and KEYTRUDA QLEX Get FDA Priority Review for Bladder Cancer Treatment
FDA grants priority review for KEYTRUDA combinations with Padcev, showing improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy.
23 October 2025
INEOS Alerts Europe on Risk to Medicine Supply
European BDO production is threatened by cheap imports from China, risking jobs and medicine supply chains. Urgent EU action is needed to block unfair competition and protect local industry.
22 October 2025
Boehringer Ingelheim's JASCAYD® Approved in China for IPF Treatment
Nerandomilast, approved in China for IPF, showed significant lung function improvement in Phase III trials. It offers favorable tolerability and is also FDA-approved in the U.S.
22 October 2025
EU Report Highlights Growth in Sustainable Aviation Fuel
EASA's report shows increased SAF production in the EU, with biofuels dominating. A 2030 target of 6% SAF blending is on track, but synthetic fuels are still developing.

The right choices in the European chemical industry

Save time with chemXplore Analytics

← Previous Next →